Publications by authors named "Martin Dowty"

Claim this Profile
D
Drug-drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450.
Vivek S Purohit, Yeamin Huh, Martin E Dowty, Anna Plotka, Alexandre Lejeune

Br J Clin Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects.
Kazuko Sagawa, Vivek Purohit, Vu Le, Hao-Jui Hsu, Martin E Dowty

AAPS J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective.
Micaela B Reddy, Tamara D Cabalu, Loeckie de Zwart, Diane Ramsden, Martin E Dowty

Clin Pharmacol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified-Release Dosage Form.
Vivek Purohit, Kazuko Sagawa, Hao-Jui Hsu, Joseph Kushner, Martin E Dowty

Clin Pharmacol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure.
Luke Fostvedt, Jian Liu, Xiaoxing Wang, Yinhua Li, Jillian Johnson, Martin Dowty

Clin Pharmacol Drug Dev· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans.
Jonathan N Bauman, Angela C Doran, Gabrielle M Gualtieri, Brian Hee, Timothy Strelevitz, Martin E Dowty

Drug Metab Dispos· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
Martin E Dowty, Ruolun Qiu, Alyssa Dantonio, Mark Niosi, Angela Doran

Drug Metab Dispos· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Xiaoxing Wang, Martin E Dowty, Sakambari Tripathy, Vu H Le, Yeamin Huh

Eur J Drug Metab Pharmacokinet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.
Anas Saadeddin, Vivek Purohit, Yeamin Huh, Mei Wong, Aurelia Maulny, Martin E Dowty

AAPS J· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.
Anas Saadeddin, Vivek Purohit, Yeamin Huh, Mei Wong, Aurelia Maulny, Martin E Dowty

AAPS J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Yeamin Huh, Anna Plotka, Hua Wei, Julia Kaplan, Nancy Raha, Martin E Dowty

Pharm Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a C-microdose approach.
Ruolun Qiu, Raman Sharma, Hua Wei, Leonid Kirkovsky, Yifan Zhou, Martin E Dowty

Br J Clin Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes.
Xiaoxing Wang, Vivek Purohit, Martin E Dowty, David Rodrigues, Lina Luo

J Clin Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients.
Jim H Hughes, Ruolun Qiu, Christopher Banfield, Martin E Dowty, Timothy Nicholas

Clin Pharmacol Drug Dev· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective.
Niresh Hariparsad, Diane Ramsden, Kunal Taskar, Justine Badée, Karthik Venkatakrishnan, Martin Dowty

Clin Pharmacol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
Manoli Vourvahis, Wonkyung Byon, Cheng Chang, Vu Le, Annette Diehl, Martin Dowty

Clin Pharmacol Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Jonathan N Bauman, Angela C Doran, Amanda King-Ahmad, Raman Sharma, Gregory S Walker, Martin E Dowty

Drug Metab Dispos· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a C-Microtracer Approach.
Ravi Shankar P Singh, Martin E Dowty, Mikhail Salganik, Joanne I Brodfuehrer, Gregory S Walker

Clin Pharmacol Drug Dev· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Xiaoxing Wang, Martin E Dowty, Ann Wouters, Svitlana Tatulych, Carol A Connell

Eur J Drug Metab Pharmacokinet· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Ellen Q Wang, Vu Le, Jennifer A Winton, Sakambari Tripathy, Sangeeta Raje, Martin E Dowty

J Clin Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Emma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, Ning Zhang, Ester Del Duca, Martin E Dowty

J Allergy Clin Immunol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Ellen Q Wang, Vu Le, Melissa O'Gorman, Sakambari Tripathy, Martin E Dowty

J Clin Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Ravi Shankar P Singh, Vivek Pradhan, Erika S Roberts, Matthew Scaramozza, Elizabeth Kieras, Martin E Dowty

Clin Transl Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Susanna Tse, Martin E Dowty, Sujatha Menon, Pankaj Gupta, Sriram Krishnaswami

J Clin Pharmacol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Brian S Gerstenberger, Catherine Ambler, Eric P Arnold, Mary-Ellen Banker, Matthew F Brown, Martin E Dowty

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis